Regenxbio (STU:RB0) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:RB0 Regenxbio Inc STU:RB0
60 GF Score
Price €6.81
GF Value €13.31
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Regenxbio Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regenxbio  (STU:RB0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Regenxbio Cyclically Adjusted PB Ratio Related Terms


Regenxbio Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Regenxbio's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenxbio Cyclically Adjusted PB Ratio Chart

Regenxbio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2.48 1.75 0.67 1.22

Regenxbio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.80 1.18 0.71 1.04

STU:RB0 vs CTNM, CRMD, AGMB: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Regenxbio's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenxbio Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Regenxbio's Cyclically Adjusted PB Ratio falls into.


STU:RB0
60GF Score
Regenxbio Inc STU:RB0
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regenxbio Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Regenxbio's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Regenxbio's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.159/333.9520*333.9520
=1.159

Current CPI (Jun. 2026) = 333.9520.

Regenxbio Quarterly Data

Book Value per Share CPI Adj_Book
201609 6.057 241.428 8.378
201612 5.792 241.432 8.012
201703 6.582 243.801 9.016
201706 6.016 244.955 8.202
201709 5.293 246.819 7.162
201712 4.871 246.524 6.598
201803 7.630 249.554 10.210
201806 8.418 251.989 11.156
201809 11.914 252.439 15.761
201812 12.324 251.233 16.382
201903 11.848 254.202 15.565
201906 11.817 256.143 15.407
201909 11.662 256.759 15.168
201912 10.842 256.974 14.090
202003 10.296 258.115 13.321
202006 9.499 257.797 12.305
202009 9.477 260.280 12.159
202012 8.238 260.474 10.562
202103 11.100 264.877 13.995
202106 10.051 271.696 12.354
202109 9.313 274.310 11.338
202112 15.692 278.802 18.796
202203 14.421 287.504 16.751
202206 13.970 296.311 15.745
202209 13.294 296.808 14.958
202212 11.170 296.797 12.568
202303 9.850 301.836 10.898
202306 8.528 305.109 9.334
202309 7.796 307.789 8.459
202312 6.407 306.746 6.975
202403 7.376 312.332 7.887
202406 6.589 314.175 7.004
202409 5.452 315.301 5.775
202412 5.061 315.605 5.355
202503 5.065 319.799 5.289
202506 3.613 322.561 3.741
202509 2.715 324.800 2.792
202512 1.719 324.054 1.772
202603 0.354 330.213 0.358
202606 1.159 333.952 1.159

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Regenxbio (STU:RB0) Overvalued in 2026?

Based on GuruFocus' analysis, Regenxbio stock appears to be undervalued. The current stock price of €6.81 is trading 48.9% below its estimated GF Value™ of €13.31. GuruFocus considers Regenxbio to be Possible Value Trap.

Key valuation signals for STU:RB0:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €13.31 vs. price of €6.81 (48.9% below fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the STU:RB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Regenxbio Business Description

Other Exchanges RGNX:USA
Address 9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
60GF Score

Get the complete analysis for STU:RB0

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.81
Price
€13.31
GF Value